Close Menu

NEW YORK – OncoCyte announced after the close of the market Friday that it has entered into an equity distribution agreement with Piper Sandler to create an at-the-market equity program under which it may sell up to an aggregate of $25 million in shares of the company’s common stock.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.